CDEK
← All drugs Report issue

Fosaprepitant

Small moleculeexperimental

Fosaprepitant, sold under the brand names Emend (US) and Ivemend (EU) among others, is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant. — Wikipedia

Clinical trial activity

10 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
8
Phase 3
6
Phase 4
0

Earliest trial started Sep 18, 2017 (NCT03237611)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07081256Phase 3Jan 3, 2025Qilu Pharmaceutical Co., Ltd.
NCT06427681Early Phase 1 (Phase 1)May 31, 2024Jinlin University, Zhuhai Beihai Biotech Co., Ltd
NCT05509634Phase 3Oct 8, 2022Jiangsu ShengDiYa Medicine Co., Ltd.
NCT05755659N/AJul 15, 2022Xijing Hospital
NCT05242874Phase 3Jan 1, 2022Henan Medical University
NCT04853147Phase 3Apr 27, 2021Sun Yat-Sen University
NCT04508400Phase 2Oct 10, 2020Sun Yat-Sen University
NCT04536558Phase 3Oct 1, 2020Jiangsu Hansoh Pharmaceutical Co., Ltd., Sun Yat-Sen University
NCT04437017Phase 3Feb 3, 2020Sun Yat-Sen University
NCT03237611Phase 2Sep 18, 2017Yeshiva University
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sun Yat-Sen UniversityAcademic/Hospital4422020
Henan Medical UniversityAcademic/Hospital1112022
Jiangsu Hansoh Pharmaceutical Co., Ltd.For profit1012020
Jiangsu ShengDiYa Medicine Co., Ltd.Government1112022
Jinlin UniversityAcademic/Hospital1012024
Qilu Pharmaceutical Co., Ltd.For profit1112025
Xijing HospitalAcademic/Hospital1112022
Yeshiva UniversityAcademic/Hospital1112017
Zhuhai Beihai Biotech Co., LtdFor profit1112024
9 organizations
Page 1 / 1